...Neurotrophic tyrosine kinase receptor 2 (TrkB; NTRK2) EXPERIMENTAL SYSTEM: Mice LICENSING STATUS: Patented; licensed to PharmatrophiX Inc....
...published online May 20, 2019 doi:10.1016/j.neuron.2019.04.032 CONTACT: Michelle Monje, Stanford University, Stanford, Calif. e-mail: mmonje@stanford.edu Sandi Wong PharmatrophiX Inc. Stanford...

...The University of North Carolina and the University of California, San Francisco; exclusively licensed to PharmatrophiX Inc....

...<0.01). The findings were published in The Journal of Clinical Investigation . Longo also cofounded PharmatrophiX Inc....
...University of North Carolina at Chapel Hill (UNC), before joining the Stanford faculty in 2005. PharmatrophiX...
...and tissue culture, the compounds blocked neuronal death caused by AD-associated b-amyloid. 9,10 Last year, PharmatrophiX...

...in 2011 or 2012. Financial terms were not disclosed. Elan Corp. plc (NYSE:ELN), Dublin, Ireland PharmatrophiX Inc....

...colitis (UC) and Crohn's. Kelly also plans to step up in-licensing. "Our recent partnership with PharmatrophiX...
...we move forward in the coming months." Last month, Elan received a global license from PharmatrophiX...
...Indianapolis, Ind. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Pfizer Inc. (NYSE:PFE), New York, N.Y. PharmatrophiX...